4XP3

Crystal structure of ERK2 in complex with an inhibitor

4XP3 の概要

• エントリーDOI: 10.2210/pdb4xp3/pdb
• 分子名称: Mitogen-activated protein kinase 1, 2-amino-1,9-dihydro-6H-purine-6-thione, SULFATE ION, ... (5 entities in total)
• 機能のキーワード: serine/threonine-protein kinase, transferase
• 由来する生物種: Rattus norvegicus (Rat)
• 細胞内の位置: Cytoplasm, cytoskeleton, spindle : P63086
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 42047.85

構造登録者

Gelin, M.,Allemand, F.,Labesse, G.,Guichou, J.F. (登録日: 2015-01-16, 公開日: 2015-08-12, 最終更新日: 2024-10-16)

主引用文献

Gelin, M.,Delfosse, V.,Allemand, F.,Hoh, F.,Sallaz-Damaz, Y.,Pirocchi, M.,Bourguet, W.,Ferrer, J.L.,Labesse, G.,Guichou, J.F.
Combining `dry' co-crystallization and in situ diffraction to facilitate ligand screening by X-ray crystallography.
Acta Crystallogr.,Sect.D, 71:1777-1787, 2015

PubMed Abstract: X-ray crystallography is an established technique for ligand screening in fragment-based drug-design projects, but the required manual handling steps - soaking crystals with ligand and the subsequent harvesting - are tedious and limit the throughput of the process. Here, an alternative approach is reported: crystallization plates are pre-coated with potential binders prior to protein crystallization and X-ray diffraction is performed directly 'in situ' (or in-plate). Its performance is demonstrated on distinct and relevant therapeutic targets currently being studied for ligand screening by X-ray crystallography using either a bending-magnet beamline or a rotating-anode generator. The possibility of using DMSO stock solutions of the ligands to be coated opens up a route to screening most chemical libraries.

PubMed: 26249358
DOI: 10.1107/S1399004715010342

実験手法

X-RAY DIFFRACTION (1.782 Å)